Zenas BioPharma (ZBIO) is up 10.6%, or $3.45 to $36.04.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Promising Developments in Zenas BioPharma’s Orelabrutinib Drive Buy Rating Amidst Competitive Advantage and Expected Share Price Upside
- Buy Rating Reaffirmed for Zenas BioPharma: Promising Orelabrutinib Developments and Autoimmune Platform Potential
- Zenas BioPharma Approves 2026 Inducement Plan
- Zenas BioPharma falls -13.0%
- InnoCare Pharma achieves primary endpoint in Phase 2b study of orelabrutinib